Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL LEVINE

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1740252048
CMS profile
123914
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,349.38

132 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,349.38 132

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL LEVINE

NPI 1740252048 · CMS profile ID 123914

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740252048?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL LEVINE, NPI 1740252048, CMS profile ID 123914. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740252048?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MICHAEL LEVINE, NPI 1740252048, CMS profile ID 123914. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740252048?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MICHAEL LEVINE, NPI 1740252048, CMS profile ID 123914, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1740252048?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

132 matching records · $2,349.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 132 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 132.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Horizon Therapeutics plc $20.4508/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797165569 CMS
AstraZeneca Pharmaceuticals LP $15.6708/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829751635 CMS
Bayer HealthCare Pharmaceuticals Inc. $21.6108/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789066957 CMS
Amgen Inc. $18.5108/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826393619 CMS
Daiichi Sankyo Inc. $20.6808/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836308599 CMS
Daiichi Sankyo Inc. $16.5008/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836317601 CMS
Daiichi Sankyo Inc. $3.7308/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836354099 CMS
Aurinia Pharma U.S., Inc. $125.6107/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841405877 CMS
Amgen Inc. $14.8407/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826393639 CMS
Amgen Inc. $4.3107/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826393643 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.4607/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763668614 CMS
Amgen Inc. $7.1107/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825619841 CMS
AMAG Pharmaceuticals, Inc. $17.3307/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 847699619 CMS
AMAG Pharmaceuticals, Inc. $3.5007/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 847699611 CMS
AstraZeneca Pharmaceuticals LP $20.1806/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829474497 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.8606/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763668616 CMS
Daiichi Sankyo Inc. $14.0706/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836302417 CMS
Daiichi Sankyo Inc. $3.7606/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836353685 CMS
Nestle HealthCare Nutrition Inc. $19.9006/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820921265 CMS
Amgen Inc. $110.8006/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825619793 CMS
Novo Nordisk Inc $18.3806/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811328537 CMS
Amgen Inc. $30.4706/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826393615 CMS
Daiichi Sankyo Inc. $3.8406/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836354591 CMS
Amgen Inc. $9.4506/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825619837 CMS
Daiichi Sankyo Inc. $20.5706/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836297505 CMS
AbbVie Inc. $4.6506/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795308473 CMS
Amgen Inc. $6.3706/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825619833 CMS
AstraZeneca Pharmaceuticals LP $20.5206/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829342311 CMS
Amgen Inc. $4.9505/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825619829 CMS
Horizon Therapeutics plc $23.0505/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797165567 CMS
AbbVie Inc. $27.8905/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795308467 CMS
Daiichi Sankyo Inc. $17.2905/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836294159 CMS
Daiichi Sankyo Inc. $3.7605/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836353949 CMS
Mallinckrodt Hospital Products Inc. $16.3105/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845366087 CMS
AstraZeneca Pharmaceuticals LP $19.3105/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829628379 CMS
Amgen Inc. $21.4605/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825619825 CMS
Daiichi Sankyo Inc. $14.7105/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836294161 CMS
Daiichi Sankyo Inc. $3.5005/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836361765 CMS
Nestle HealthCare Nutrition Inc. $24.4804/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820921261 CMS
Merck Sharp & Dohme Corporation $17.6404/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848328111 CMS
Amgen Inc. $18.2104/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825619821 CMS
Amgen Inc. $24.9304/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826393637 CMS
Amgen Inc. $6.4304/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825619817 CMS
Fresenius USA Marketing, Inc. $18.6704/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849416249 CMS
Daiichi Sankyo Inc. $16.6404/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836284783 CMS
Daiichi Sankyo Inc. $3.9804/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836358603 CMS
Daiichi Sankyo Inc. $16.7204/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836287003 CMS
Daiichi Sankyo Inc. $2.6604/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836353721 CMS
AbbVie Inc. $18.5203/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795308461 CMS
AbbVie Inc. $17.5203/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795308457 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,701.13 110
PY2020 $5,218.33 122
PY2021 $2,349.38 132
PY2022 $1,728.33 104
PY2023 $3,400.82 124
PY2024 $3,244.37 173
PY2025 $3,033.30 141

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $219,472.34 20
PY2024 Principal investigator $131,939.15 35
PY2023 Principal investigator $365,370.61 45
PY2022 Principal investigator $81,124.78 13
PY2021 Principal investigator $12,247.60 3
PY2020 Principal investigator $5,792.70 6
PY2019 Recipient $1,199.21 15
PY2019 Principal investigator $28,976.90 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

20 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $22,500.00 10/15/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER
Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) No dispute reported 06/30/2026 1185548095
Principal investigator 1 Alnylam Pharmaceuticals Inc. $21,248.30 09/17/2025 Non-covered Recipient Entity
Amicis Research Center
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215523791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,585.00 09/17/2025 Non-covered Recipient Entity
Amicis Research Center
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215523793
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,000.00 09/17/2025 Non-covered Recipient Entity
Amicis Research Center
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215523795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,000.00 09/17/2025 Non-covered Recipient Entity
Amicis Research Center
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215523797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,000.00 09/17/2025 Non-covered Recipient Entity
Amicis Research Center
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215523799
Principal investigator 1 CSL Behring $5,841.00 09/17/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665851
Principal investigator 1 CSL Behring $16.71 08/05/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665985
Principal investigator 1 CSL Behring $8,761.50 07/16/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665847
Principal investigator 1 CSL Behring $894.52 06/26/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $700.00 06/02/2025 Non-covered Recipient Entity
Amicis Research Center
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215523769
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,250.00 06/02/2025 Non-covered Recipient Entity
Amicis Research Center
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215523771
Principal investigator 1 CSL Behring $367.52 04/28/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665955
Principal investigator 1 CSL Behring $324.32 04/24/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665953
Principal investigator 1 CSL Behring $3,370.50 04/16/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665845
Principal investigator 1 CSL Behring $16.71 04/09/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665893
Principal investigator 1 CSL Behring $423.76 03/31/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665873
Principal investigator 1 CSL Behring $604.78 02/28/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665877
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,282.20 02/26/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER
A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease No dispute reported 06/30/2026 1185548093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $130,285.52 02/21/2025 Non-covered Recipient Entity
Amicis Research Center
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215523753